glp1ledger

Medicaid GLP-1 Coverage by State: Who Covers Wegovy and Zepbound for Weight Loss in 2026

Thirteen state Medicaid programs covered GLP-1s for obesity in January 2026, down from 16. Massachusetts dropped out in July. The state list, what changed, and what happened to prescriptions.

Ronald R · Edited by Caroline S · Published 2026-11-19

Illustration: A blank desk calendar on a light wooden table, with a hand holding a pen beside it.
Illustration

Whether Medicaid pays for a GLP-1 prescribed for weight loss depends on the state, and the list got shorter in 2026. Federal law requires state Medicaid programs to cover nearly every FDA-approved drug, but it lets each state leave out drugs used for weight loss. So Ozempic and Mounjaro for type 2 diabetes are covered everywhere, Wegovy for heart protection and Zepbound for sleep apnea are covered everywhere for those uses, and Wegovy or Zepbound purely for weight loss is covered only where a state has chosen to pay.

This page sets out that choice state by state, dated, and records what changed during the year. The register comes from KFF's January 2026 analysis, the most recent complete state-by-state count. Later changes come from the documents named beside each one. The legal mechanism behind the optional exclusion — the same statute that shapes Medicare and why the manufacturer savings cards exclude government beneficiaries — is set out on GLP-1 insurance coverage and is not repeated here.

The register: 13 states in January 2026

KFF's analysis (Elizabeth Williams, published 16 January 2026) counted 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. Its 2025 Medicaid budget survey had found 16 in October 2025. The figures below are from the map dataset published with that analysis, read on 19 November 2026.

State Status in KFF's January 2026 count Change recorded since
Delaware Covers GLP-1s for obesity —
Kansas Covers GLP-1s for obesity —
Massachusetts Covers GLP-1s for obesity Ended 1 July 2026 (see below)
Michigan Covers GLP-1s for obesity Higher BMI threshold from the first quarter of 2026 (JAMA study methods)
Minnesota Covers GLP-1s for obesity —
Mississippi Covers GLP-1s for obesity —
Missouri Covers GLP-1s for obesity —
North Carolina Covers GLP-1s for obesity Dropped October 2025, reinstated December 2025
Rhode Island Covers GLP-1s for obesity —
Tennessee Covers GLP-1s for obesity Coverage began August 2025 (JAMA study methods)
Utah Covers GLP-1s for obesity KFF: funding limited to state fiscal year 2026, which ended 30 June 2026; current status not confirmed
Virginia Covers GLP-1s for obesity —
Wisconsin Covers GLP-1s for obesity —

A dash means no change was found in the documents read for this page, not that the state was re-checked on the day. Covered states typically add prior authorisation, BMI thresholds or other conditions, which KFF notes "can further limit access".

Seven more states cover a weight-loss drug, but no GLP-1. KFF lists Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania and Texas as reporting coverage of one or more weight-loss drugs without covering any GLP-1. The other states, and the District of Columbia, are listed as not covering weight-loss drugs.

What changed in 2026

Four states left on 1 January. California, New Hampshire, Pennsylvania and South Carolina ended weight-loss GLP-1 coverage at the start of the year. KFF attributes this to state budget pressure and the cost of coverage.

Massachusetts left on 1 July. A June 2026 formulary notice from Mass General Brigham Health Plan, one of MassHealth's accountable care organisations, relays the change: "effective July 1, 2026, MassHealth will no longer cover medications used solely for weight loss, including GLP-1 agents". It applies to GLP-1s prescribed for weight loss, including off-label use of diabetes GLP-1s, and to oral weight-loss drugs, across all MassHealth members. The same notice says:

  • Wegovy injection becomes the sole preferred non-diabetes GLP-1, covered for conditions such as a BMI above 27 with established cardiovascular disease, MASH (a form of fatty liver disease), and a BMI above 30 with moderate to severe obstructive sleep apnea.
  • The Wegovy tablet is covered only after a heart attack, stroke or symptomatic peripheral artery disease, and for members under 21.
  • Zepbound becomes non-preferred and requires a "step-through" with Wegovy injection for sleep apnea.
  • Members with diabetes or prediabetes need a new prescription for a diabetes medicine.
  • Existing weight-loss approvals could be filled through 30 June 2026.

MassHealth's own pharmacy notices refused automated access when this page was written, so the plan notice is the document quoted.

Utah's year may have run out. KFF marked Utah's coverage with a note that funding was "limited to FY 2026". Utah's fiscal year ended on 30 June 2026. Utah Medicaid's prior-authorisation page still lists a form titled GLP-1 Medications for Weight-related Comorbidities, but the form itself refused automated access, so this page does not state whether coverage continues.

Indiana says it will join. On 30 July 2026, Indiana's governor directed the state's Family and Social Services Administration to take part in the federal BALANCE model (below). Indiana Medicaid "will pay $85.16 of the $245 monthly cost per person", with the rest from federal funds and manufacturer discounts. The report adds that "exact details about eligibility criteria and timing are not yet available, as the agreement is still being finalized". Until those terms are published, Indiana is a planned entry, not a covering state.

What happened to prescriptions when coverage ended

A study published in JAMA on 16 November 2026 (Shuey, Wharam, Luo, Nguyen and Anderson, University of Pittsburgh and Duke; PMID 43037973) measured the four January withdrawals using Medicaid's State Drug Utilization Data, which counts every outpatient prescription a state's Medicaid program pays for. It compared the four states with ten that kept coverage throughout 2025 and early 2026.

Weight-loss GLP-1 prescriptions per quarter Q4 2025 Q1 2026 Change
California 523,015 126,912 −75.7%
Pennsylvania 129,524 5,814 −95.5%
New Hampshire 5,322 625 −88.3%
South Carolina 3,316 1,269 −61.7%
Ten states that kept coverage (total) 350,867 325,406 −7.3%

Per 100,000 Medicaid beneficiaries, the four states fell from 2,914 to 421, against 3,006 to 2,758 in the comparison states. The difference-in-differences estimate was −2,245 prescriptions per 100,000 beneficiaries per quarter (95% CI −4,047 to −443), a relative change of −84%. Prescriptions for diabetes GLP-1s did not change significantly differently between the two groups (−266; 95% CI −912 to 380), so the study found no sign of patients being switched in bulk to Ozempic or Mounjaro.

The authors estimate that 175,500 to 526,600 fewer beneficiaries filled a weight-loss GLP-1 after coverage ended, depending on whether people fill one or three prescriptions a quarter. Prescribing did not fall to zero, which they suggest may reflect Wegovy and Zepbound being prescribed for covered uses such as sleep apnea.

What the study does not show: whether those people kept taking a GLP-1 by another route, whether their weight or health changed, or what happened in Massachusetts, which left after the study window. It counts paid prescriptions, nothing more. Results were similar when Massachusetts and Michigan, which raised their BMI thresholds in early 2026, were removed from the comparison group.

For scale, KFF reports that Medicaid GLP-1 prescriptions for all uses rose from about 1 million in 2019 to over 8 million in 2024, and gross spending from about $1 billion to almost $9 billion, before the rebates states receive.

The BALANCE model

BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a CMS Innovation Center model in which CMS negotiates GLP-1 prices and coverage terms with manufacturers on behalf of state Medicaid agencies. The CMS model page (last modified 29 September 2026, read 19 November 2026) states that participation is voluntary for manufacturers and states, that state agencies can join "beginning in May 2026 through January 1, 2027", and that coverage "will depend on participation by drug manufacturers and states" and "will not guarantee coverage for any individual". People covered through it are offered a lifestyle support programme, provided by the manufacturer at no cost.

KFF's explainer (11 May 2026) records that the Medicaid price is confidential, that the state application deadline was 31 July 2026, and that CMS announced on 21 April 2026 it would not proceed with the Medicare part of the model in 2027. For people on Medicare, including those with both Medicare and Medicaid, the separate Medicare GLP-1 Bridge runs to 31 December 2027.

As of 19 November 2026, Indiana is the only state this page found reported as joining. The CMS model page names no participating state.

What this page cannot tell you

  • Today's status in every state. The register is KFF's January 2026 count with the later changes this page could document. States change preferred drug lists quarterly, and managed care plans inside a state can apply their own criteria. The state Medicaid agency's preferred drug list, or the member's plan, is the deciding record.
  • Who qualifies in a covering state. BMI thresholds, required diagnoses, prior trials of other drugs and renewal rules differ by state and are not compared here.
  • Health effects of losing coverage. No published study has yet measured them.

Coverage decisions sit with the state and the plan, and treatment decisions with a prescriber. For people not on Medicaid, the self-pay routes are on the GLP-1 cost page and Medicare's rules are on does Medicare cover GLP-1s. The paperwork step that every covering state uses is explained in GLP-1 prior authorization.

Sources and dates

  • KFF, Elizabeth Williams, Medicaid Coverage of and Spending on GLP-1s, published 16 January 2026, and its state map dataset (Datawrapper GL0OB), read 19 November 2026.
  • KFF, Meredith Freed, Juliette Cubanski and Elizabeth Williams, What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, 11 May 2026, read 19 November 2026.
  • Centers for Medicare & Medicaid Services, BALANCE Model page, last modified 29 September 2026, read 19 November 2026.
  • Shuey B, Wharam JF, Luo J, Nguyen E, Anderson TS. Glucagon-Like Peptide-1 Utilization Following Withdrawal of Medicaid Coverage for Weight Loss. JAMA, published online 16 November 2026. doi:10.1001/jama.2026.22008. PMID 43037973; author manuscript PMC13775135, read 19 November 2026.
  • Mass General Brigham Health Plan, Formulary Updates, June 2026 (MassHealth), anti-obesity coverage update effective 1 July 2026, read 19 November 2026.
  • Indiana Capital Chronicle (Mackenzi Klemann), Indiana Medicaid will cover GLP-1s for obesity, 30 July 2026, via Indiana Public Media, read 19 November 2026.
  • Utah Medicaid, Pharmacy prior authorization page, read 19 November 2026 (linked form not retrievable).

Frequently asked questions

Does Medicaid cover Wegovy or Zepbound for weight loss?

Only in some states, because weight-loss coverage is optional under federal law. KFF counted 13 state programs covering GLP-1s for obesity in January 2026, and Massachusetts has since left the list. Every state must still cover GLP-1s approved for type 2 diabetes, and must cover Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea when those uses are approved. Covered states usually require prior authorisation.

Which states' Medicaid programs cover GLP-1s for weight loss?

As of KFF's January 2026 count: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin. Since then Massachusetts ended weight-loss coverage on 1 July 2026, and KFF noted that Utah's funding was limited to state fiscal year 2026, which ended on 30 June 2026. The state's own Medicaid preferred drug list is the record that decides a claim.

Does Medicaid cover Ozempic?

For type 2 diabetes, yes: Ozempic is approved for diabetes, and state Medicaid programs must cover nearly all FDA-approved drugs for their approved uses. Covering Ozempic or any GLP-1 for weight loss is the optional part. MassHealth's 2026 change explicitly includes off-label use of diabetes GLP-1s for weight loss in what it no longer covers.

What is the BALANCE model?

A voluntary federal programme in which the CMS Innovation Center negotiates GLP-1 prices and coverage terms with manufacturers on behalf of state Medicaid agencies. States can join on a date of their choosing from May 2026 to 1 January 2027. CMS says participation does not guarantee coverage for any individual. Indiana is the one state reported as joining; the Medicare part of the model was postponed in April 2026.

What happened to patients when states dropped coverage?

Prescriptions fell sharply. The November 2026 JAMA study found weight-loss GLP-1 prescriptions in California, New Hampshire, Pennsylvania and South Carolina fell about 84% more than in states that kept coverage, with no matching rise in diabetes GLP-1 prescriptions. The authors estimate 175,500 to 526,600 fewer beneficiaries filled one. The study counts prescriptions, not health outcomes. Anyone losing coverage mid-treatment has reasons to talk to their prescriber about options before supply runs out.